{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:41:50Z","timestamp":1791891710689,"version":"4.3.4"},"reference-count":83,"publisher":"Radcliffe Medical Media Ltd","issue":"1","license":[{"start":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T00:00:00Z","timestamp":1556582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Cardiol"],"published-print":{"date-parts":[[2019,4,30]]},"abstract":"<jats:p>Most patients with stable angina can be managed with lifestyle changes, especially smoking cessation and regular exercise, along with taking antianginal drugs. Randomised controlled trials show that antianginal drugs are equally effective and none of them reduced mortality or the risk of MI, yet guidelines prefer the use of beta-blockers and calcium channel blockers as a first-line treatment. The European Society of Cardiology guidelines for the management of stable coronary artery disease provide classes of recommendation with levels of evidence that are well defined. The National Institute for Health and Care Excellence (NICE) guidelines for the management of stable angina provide guidelines based on cost and effectiveness using the terms first-line and second-line therapy. Both guidelines recommend using low-dose aspirin and statins as disease-modifying agents. The aim of this article is to critically appraise the guidelines\u2019 pharmacological recommendations for managing patients with stable angina.<\/jats:p>","DOI":"10.15420\/ecr.2018.26.1","type":"journal-article","created":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T17:43:08Z","timestamp":1557250988000},"page":"18-22","source":"Crossref","is-referenced-by-count":39,"title":["Stable Angina Medical Therapy Management Guidelines: A Critical Review of Guidelines from the European Society of Cardiology and National Institute for Health and Care Excellence"],"prefix":"10.15420","volume":"14","author":[{"given":"Talla A","family":"Rousan","sequence":"first","affiliation":[{"name":"University of Oklahoma Health Sciences Center and Veteran Affairs Medical Center, Oklahoma City, Oklahoma, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udho","family":"Thadani","sequence":"additional","affiliation":[{"name":"University of Oklahoma Health Sciences Center and Veteran Affairs Medical Center, Oklahoma City, Oklahoma, US"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2019,4,30]]},"reference":[{"key":"ref0","unstructured":"1. Heberden W. Some account of a disorder of the breast. Medical Transactions 1772;2:59-67."},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Abrams J, Thadani U. Therapy of stable angina pectoris: the uncomplicated patient. Circulation 2005;112: e255-9.","DOI":"10.1161\/CIRCULATIONAHA.104.526699"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Thadani U. Current medical management of chronic stable angina. J Cardiovasc Pharmacol Ther 2004;9(Suppl 1):S11-29.","DOI":"10.1177\/107424840400900103"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart diseases. J Am Coll Cardiol 2012; 60:e44-e164.","DOI":"10.1016\/j.jacc.2012.07.013"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Opie LH. Angina pectoris: the evolution of concepts. J Cardiovasc Pharmacol Ther 2004;9:S3-9.","DOI":"10.1177\/107424840400900102"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Short and long-acting oral nitrates for stable angina pectoris","DOI":"10.1007\/BF00877415"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Ointments and transdermal nitroglycerin patches for stable angina pectoris","DOI":"10.1007\/BF00877416"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina","DOI":"10.1001\/jama.281.20.1927"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Challenges with nitrate therapy and nitrate tolerance: prevalence, prevention, and clinical relevance","DOI":"10.1007\/s40256-014-0072-5"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"A randomized, double-blind, placebo-controlled, crossover, dose-ranging multicenter study to determine the effect of sublingual nitroglycerin spray on exercise capacity in patients with chronic stable angina","DOI":"10.4137\/CMC.S9132"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Side effects of using nitrates to treat angina","DOI":"10.1517\/14740338.5.5.667"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Acute and chronic antianginal efficacy of continuous twenty-four-hour application of transdermal nitroglycerin","DOI":"10.1016\/0002-9149(91)90229-E"},{"key":"ref12","unstructured":"13. Prichard BN, Owens CW. Mode of action of beta-adrenergic blocking drugs in hypertension. Clin Physiol Biochem 1990;8:1-10."},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Beta-adrenergic receptor blocking drugs in angina pectoris","DOI":"10.2165\/00003495-197407010-00005"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Comparison of the immediate effects of five beta-adrenoreceptor-blocking drugs with different ancillary properties in angina pectoris","DOI":"10.1056\/NEJM197904053001402"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Comparison of five beta-adrenoreceptor antagonists with different ancillary properties during sustained twice daily therapy in angina pectoris","DOI":"10.1016\/0002-9343(80)90361-7"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Comparison of adrenergic beta-receptor antagonists in angina pectoris","DOI":"10.1136\/bmj.1.5846.138"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","DOI":"10.1016\/S0140-6736(98)11181-9"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","DOI":"10.1016\/S0140-6736(99)04440-2"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure","DOI":"10.1056\/NEJM199605233342101"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Beta-Blocker Heart Attack Study Group. The beta-blocker heart attack trial. JAMA 1981;246:2073-4.","DOI":"10.1001\/jama.246.18.2073"},{"key":"ref21","unstructured":"22. Hjalmarson A, Herlitz J, Holmberg S, et al. The G\u00f6teborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation 1983;67(6 Pt 2):I26-32."},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"The impact of beta-blockers on mortality in stable angina: a meta-analysis","DOI":"10.1258\/smj.2011.011274"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Beta-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease","DOI":"10.1001\/jama.2012.12559"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Beta blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial","DOI":"10.1161\/CIRCOUTCOMES.114.001073"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Clinical outcomes with beta-blockers for myocardial infarction: a meta-analysis of randomized trials","DOI":"10.1016\/j.amjmed.2014.05.032"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Verapamil: a review of its pharmacological properties and therapeutic use","DOI":"10.2165\/00003495-197815030-00001"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Diltiazem: a review of its pharmacological properties and therapeutic efficacy","DOI":"10.2165\/00003495-198529050-00001"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Amlodipine in chronic stable angina: results of a multicenter double-blind crossover trial","DOI":"10.1016\/0002-8703(95)90281-3"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Clinical safety and efficacy of once-a-day amlodipine for chronic stable angina pectoris","DOI":"10.1016\/0002-9149(88)90647-9"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Combination of calcium channel blockers and beta-adrenoceptor blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers","DOI":"10.1046\/j.1365-2125.1999.00924.x"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32. Husted SE, Ohman EM. Pharmacological and emerging therapies in the treatment of chronic angina. Lancet 386(9994):691-701.","DOI":"10.1016\/S0140-6736(15)61283-1"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"The risk of cardiovascular side effects with anti-anginal drugs","DOI":"10.1080\/14740338.2016.1238457"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Nicorandil for angina","DOI":"10.1136\/dtb.1995.331289"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"2013 ESC guidelines on the management of stable coronary artery diseas","DOI":"10.1093\/eurheartj\/eht296"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"36. Camm AJ, Maltz MB. A controlled single-dose study of the efficacy, dose response and duration of action of nicorandil in angina pectoris. Am J Cardiol 1989;63:J61-5.","DOI":"10.1016\/0002-9149(89)90207-5"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"37. Thadani U. Can nicorandil treat angina pectoris effectively? Nat Clin Pract Cardiovasc Med 2005;2:186-7.","DOI":"10.1038\/ncpcardio0159"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial","DOI":"10.1016\/S0140-6736(02)08265-X"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Nicorandil, gastrointestinal adverse drug reactions and ulcerations: a systematic review","DOI":"10.1007\/s12325-016-0294-9"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"40. Cocco G, Rousseau MF, Bouvy T, et al. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol 1992;20:131-8.","DOI":"10.1097\/00005344-199220010-00017"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal","DOI":"10.1517\/14656566.2012.740458"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"42. Codolosa JN, Acharjee S, Figueredo VM. Update on ranolazine in the management of angina. Vasc Health Risk Manag 2014;10:353-62.","DOI":"10.2147\/VHRM.S40477"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina","DOI":"10.1016\/j.jacc.2003.11.045"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial","DOI":"10.1001\/jama.291.3.309"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial","DOI":"10.1016\/j.jacc.2006.05.044"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina)","DOI":"10.1016\/j.jacc.2013.02.011"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve","DOI":"10.1093\/eurheartj\/ehv647"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Antagonist molecules in the treatment of angina","DOI":"10.1517\/14656566.2013.834329"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Modified-release formulation of trimetazidine for exceptional control of angina pectoris: fact or fiction","DOI":"10.2165\/00129784-200505050-00006"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"TRIMetazidine in POLand","DOI":"10.1053\/euhj.2001.2896"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Allopurinol as a cardiovascular drug","DOI":"10.1097\/CRD.0b013e318229a908"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol","DOI":"10.2165\/00003088-200746080-00001"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial","DOI":"10.1016\/S0140-6736(10)60391-1"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"54. O'Flynn N, Timmis A, Henderson R, et al. Management of stable angina: summary of NICE guidance. BMJ 2011;343:d4147.","DOI":"10.1136\/bmj.d4147"},{"key":"ref54","unstructured":"55. National Institute for Health and Care Excellence. Stable Angina: Management. London: NICE, 2011. Available at: https:\/\/www.nice.org.uk\/guidance\/cg126 (accessed 23 February 2019)."},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial","DOI":"10.1161\/01.CIR.0000048143.25023.87"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Ferrari R, Ceconi C, Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease","DOI":"10.1586\/erc.11.99"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial","DOI":"10.1093\/eurheartj\/ehn571"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study","DOI":"10.1007\/s00392-011-0402-4"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"60. K\u00f6ster R, Kaehler J, Meinertz T. Treatment of stable angina pectoris by ivabradine in every day practice: the REDUCTION study. Am Heart J 2009;158:e51-7.","DOI":"10.1016\/j.ahj.2009.06.008"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Ivabradine in combination with beta-blocker reduces symptoms and improves quality of life in elderly patients with stable angina pectoris: age-related results from the ADDITIONS study","DOI":"10.1016\/j.exger.2014.09.002"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Ivabradine in stable coronary artery disease without clinical heart failure","DOI":"10.1056\/NEJMoa1406430"},{"key":"ref62","unstructured":"63. Thadani U. Chronic stable angina pectoris. In: Crawford MH, DiMarco JP, Paulus WJ (eds). Cardiology. 3rd ed. Philadelphia: Saunders. 2010 283-99."},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Drug therapy for stable angina pectoris","DOI":"10.1007\/s40265-017-0691-7"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Management of stable angina - current guidelines: a critical appraisal","DOI":"10.1007\/s10557-016-6681-2"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Anti-anginal drugs-beliefs and evidence: systematic review covering 50 years of medical treatment","DOI":"10.1093\/eurheartj\/ehy504"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial","DOI":"10.1016\/S0140-6736(08)61170-8"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Expert consensus document: A 'diamond' approach to personalized treatment of angina","DOI":"10.1038\/nrcardio.2017.131"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Is smokeless tobacco a risk factor for coronary heart disease? A systematic review of epidemiological studies","DOI":"10.1097\/01.hjr.0000114971.39211.d7"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial","DOI":"10.1161\/01.CIR.0000121360.31954.1F"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"71. Second International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2;349-60.","DOI":"10.1016\/S0140-6736(88)92833-4"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"72. Juul-Moller S, Edvardsson N, Jahnmatz B, et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992;340:1421- 5.","DOI":"10.1016\/0140-6736(92)92619-Q"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","DOI":"10.1056\/NEJMoa060989"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","DOI":"10.1016\/S0140-6736(02)09327-3"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","DOI":"10.1056\/NEJMoa050461"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"76. ACCORD Study Group, Cushman WC, Evans GW, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362;1575-85.","DOI":"10.1056\/NEJMoa1001286"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"A randomized trial of intensive versus standard blood-pressure control","DOI":"10.1056\/NEJMoa1511939"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"78. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.","DOI":"10.1056\/NEJMoa0802743"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"The Cardiac Insufficiency Bisoprolol Study II","DOI":"10.1016\/S0140-6736(05)74356-7"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"80. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429-35. PMID: 2883575.","DOI":"10.1056\/NEJM198706043162301"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","DOI":"10.1016\/S0140-6736(03)14283-3"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"82. Pfeffer MA, Braunwald E, Moy\u00e9 LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992:327;669-77.","DOI":"10.1056\/NEJM199209033271001"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"The updated NICE guidelines: cardiac CT as the first-line test for coronary artery disease","DOI":"10.1007\/s12410-017-9412-6"}],"container-title":["European Cardiology Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ecrjournal.com\/articles\/stable-angina-medical-therapy-management-guidelines-critical-review-guidelines-european","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T13:50:54Z","timestamp":1663422654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ecrjournal.com\/articles\/stable-angina-medical-therapy-management-guidelines-critical-review-guidelines-european"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,30]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.15420\/ecr.2018.26.1","relation":{},"ISSN":["1758-3764","1758-3756"],"issn-type":[{"value":"1758-3764","type":"electronic"},{"value":"1758-3756","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4,30]]}}}